ILEI requires oncogenic Ras for the epithelial to mesenchymal transition of hepatocytes and liver carcinoma progression

Oncogene

Volumn 28, Issue 5, 2009, Pages 638-650

  Lahsnig, C ^a   Mikula, M ^b   Petz, M ^b   Zulehner, G ^a   Schneller, D ^a   Van Zijl, F ^a   Huber, H ^b   Csiszar, A ^b   Beug, H ^b   Mikulits, W ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

Author keywords

Epithelial to mesenchymal transition; HCC; Hepatocyte; ILEI; Tumor progression

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BETA CATENIN; CYCLIN DEPENDENT KINASE INHIBITOR 2D; INTERLEUKIN LIKE EMT INDUCER; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN P19; PROTEIN ZO1; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENICITY; CELL DIFFERENTIATION; CELL MATURATION; CELL MIGRATION; CELL TRANSFORMATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LUNG METASTASIS; MESENCHYME CELL; MOUSE; MUTANT; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; BETA CATENIN; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CYTOKINES; DISEASE PROGRESSION; EPITHELIAL CELLS; FEMALE; GENES, RAS; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; MALE; MESODERM; MICE; MICE, SCID; NEOPLASM PROTEINS; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; STAT3 TRANSCRIPTION FACTOR; TISSUE DISTRIBUTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 59649107672     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.418     Document Type: Article

References (41)

1. Breuhahn K, Longerich T, Schirmacher P. (2006). Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 25: 3787-3800.
2. Bruix J, Boix L, Sala M, Llovet JM. (2004). Focus on hepatocellular carcinoma. Cancer Cell 5: 215-219.
3. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS et al. (2006). Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130: 1117-1128.
4. Campbell JS, Hughes SD, Gilbertson DG, Palmer TE, Holdren MS, Haran AC et al. (2005). Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci USA 102: 3389-3394.
5. Campbell JS, Johnson MM, Bauer RL, Hudkins KL, Gilbertson DG, Riehle KJ et al. (2007). Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis. Differentiation 75: 843-852.
6. Edmondson HA, Steiner PE. (1954). Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7: 462-503.
7. Eger A, Aigner K, Sonderegger S, Dampier B, Oehler S, Schreiber M et al. (2005). DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 24: 2375-2385.
8. El-Serag HB, Rudolph KL. (2007). Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2776.
9. Fischer AN, Fuchs E, Mikula M, Huber H, Beug H, Mikulits W. (2007). PDGF essentially links TGF-beta signaling to nuclear beta-catenin accumulation in hepatocellular carcinoma progression. Oncogene 26: 3395-3405.
10. Fischer AN, Herrera B, Mikula M, Proell V, Fuchs E, Gotzmann J et al. (2005). Integration of Ras subeffector signaling in TGF-{beta} mediated late stage hepatocarcinogenesis. Carcinogenesis 26: 931-942.
11. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA et al. (2001). Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20: 2499-2513.
12. Giannelli G, Bergamini C, Fransvea E, Sgarra C, Antonaci S. (2005). Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology 129: 1375-1383.
13. Giebel B, Wodarz A. (2006). Tumor suppressors: control of signaling by endocytosis. Curr Biol 16: R91-R92.
14. Gotzmann J, Fischer AN, Zojer M, Mikula M, Proell V, Huber H et al. (2006). A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes. Oncogene 25: 3170-3185.
15. Gotzmann J, Huber H, Thallinger C, Wolschek M, Jansen B, Schulte-Hermann R et al. (2002). Hepatocytes convert to a fibroblastoid phenotype through the cooperation of TGF-beta1 and Ha-Ras: steps towards invasiveness. J Cell Sci 115: 1189-1202.
16. Grunert S, Jechlinger M, Beug H. (2003). Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 4: 657-665.
17. Herath NI, Leggett BA, MacDonald GA. (2006). Review of genetic and epigenetic alterations in hepatocarcinogenesis. J Gastroenterol Hepatol 21: 15-21.
18. Huber MA, Kraut N, Beug H. (2005). Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17: 548-558.
19. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED et al. (2007). Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 213: 374-383.
20. Jechlinger M, Sommer A, Moriggl R, Seither P, Kraut N, Capodiecci P et al. (2006). Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest 116: 1561-1570.
21. Kensler TW, Qian GS, Chen JG, Groopman JD. (2003). Translational strategies for cancer prevention in liver. Nat Rev Cancer 3: 321-329.
22. Kondoh N, Wakatsuki T, Hada A, Shuda M, Tanaka K, Arai M et al. (2001). Genetic and epigenetic events in human hepatocarcinogenesis. Int J Oncol 18: 1271-1278.
23. Lacher MD, Tiirikainen MI, Saunier EF, Christian C, Anders M, Oft M et al. (2006). Transforming growth factor-beta receptor inhibition enhances adenoviral infectability of carcinoma cells via up-regulation of Coxsackie and Adenovirus Receptor in conjunction with reversal of epithelial-mesenchymal transition. Cancer Res 66: 1648-1657.
24. Lee HC, Kim M, Wands JR. (2006a). Wnt/Frizzled signaling in hepatocellular carcinoma. Front Biosci 11: 1901-1915.
25. Lee TK, Man K, Poon RT, Lo CM, Yuen AP, Ng IO et al. (2006b). Signal transducers and activators of transcription 5b activation enhances hepatocellular carcinoma aggressiveness through induction of epithelial-mesenchymal transition. Cancer Res 66: 9948-9956.
26. Macheiner D, Heller G, Kappel S, Bichler C, Stattner S, Ziegler B et al. (2006). NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma. J Hepatol 45: 81-89.
27. Mikula M, Fuchs E, Huber H, Beug H, Schulte-Hermann R, Mikulits W. (2004). Immortalized p19ARF null hepatocytes restore liver injury and generate hepatic progenitors after transplantation. Hepatology 39: 628-634.
28. Ogata H, Chinen T, Yoshida T, Kinjyo I, Takaesu G, Shiraishi H et al. (2006a). Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-beta1 production. Oncogene 25: 2520-2530.
29. Ogata H, Kobayashi T, Chinen T, Takaki H, Sanada T, Minoda Y et al. (2006b). Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology 131: 179-193.
30. Pardali K, Moustakas A. (2007). Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 1775: 21-62.
31. Pietras K, Sjoblom T, Rubin K, Heldin CH, Ostman A. (2003). PDGF receptors as cancer drug targets. Cancer Cell 3: 439-443.
32. Rossmanith W, Schulte-Hermann R. (2001). Biology of transforming growth factor beta in hepatocarcinogenesis. Microsc Res Tech 52: 430-436.
33. Silva CM. (2004). Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 23: 8017-8023.
34. Tannapfel A, Busse C, Weinans L, Benicke M, Katalinic A, Geissler F et al. (2001). INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas. Oncogene 20: 7104-7109.
35. Thiery JP, Sleeman JP. (2006). Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7: 131-142.
36. Thorgeirsson SS, Grisham JW. (2002). Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31: 339-346.
37. Waerner T, Alacakaptan M, Tamir I, Oberauer R, Gal A, Brabletz T et al. (2006). ILEI: a cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells. Cancer Cell 10: 227-239.
38. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C et al. (2004). Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117: 927-939.
39. Yang SF, Wang SN, Wu CF, Yeh YT, Chai CY, Chunag SC et al. (2007). Altered p-STAT3 (tyr705) expression is associated with histological grading and intratumour microvessel density in hepatocellular carcinoma. J Clin Pathol 60: 642-648.
40. Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE et al. (2001). SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 28: 29-35.
41. Zhou L, Rui JA, Wang SB, Chen SG, Qu Q, Chi TY et al. (2007). Outcomes and prognostic factors of cirrhotic patients with hepatocellular carcinoma after radical major hepatectomy. World J Surg 31: 1782-1787.